Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

Reports Q4 revenue $7.6B, consensus $7.15B. “Gilead (GILD) delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Gilead Sciences, a leader in HIV drugs, faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033, making diversification crucial. The current stock price at $95+ implies 5 ...

Today's Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc. (UBER), Comcast Corp. (CMCSA) and Gilead Sciences, Inc. (GILD), as well as a micro-cap ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A strong defensive performance led host Highland past Mount Gilead in a Monday night girls’ basketball game. In the contest, which was being made up from Saturday, the Lady Scots held their opponents ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers, paving the ...